ReviewBrain pathology (Zurich, Switzerland)2013
Emerging insights into the ependymoma epigenome.
Review in Brain pathology (Zurich, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Morphology-based molecular classification of spinal cord ependymomas using deep neural networks.Brain pathology (Zurich, Switzerland) · 2024Article
- The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models.International journal of molecular sciences · 2021Article
- Harnessing brain development to understand brain tumours.Development (Cambridge, England) · 2021Article
- Put away your microscopes: the ependymoma molecular era has begun.Current opinion in oncology · 2017Review
- Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival.Journal of neuro-oncology · 2017Article
- The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.Acta neuropathologica · 2017Article
- Treatment implications of posterior fossa ependymoma subgroups.Chinese journal of cancer · 2016Article
- Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.Cancer research · 2016Article
- Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.Neuro-oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ependymoma is the third most common pediatric brain tumor, yet because of the paucity of effective therapeutic interventions, 45% of patients remain incurable. Recent transcriptional and copy number profiling of the disease has identified few driver genes and in fact points to a balanced genomic profile. Candidate gene approaches looking at hypermethylated promoters and genome-wide epigenetic arrays suggest that DNA methylation may be critical to ependymoma pathogenesis. This review attempts to highlight existing and emerging evidence implicating the ependymoma epigenome as a key player and that epigenetic modifiers may offer new targeted therapeutic avenues for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.